Hereditary Angioedema Treatment Market: Surge in Awareness about Rare Genetic Diseases Contributes to Growth

The prevalence of rare diseases has surged in recent years, as the tracking of their incidence has improved around the world in the past few decades. This is particularly significant for genetic diseases, as standardized screenings and tests are few, as such, making it hard to determine how many people are affected by them. Hereditary angioedema, also known as HAE, has been in the spotlight, as government and non-government organizations around the world work to raise public awareness to increase diagnosis and improve treatment. According to a report by Transparency Market Research on the global hereditary angioedema treatment market, in 2018, the treatment for HAE was sought mainly in North America, making it the largest regional market, accounting for over three-fourth of the global market share. This can be attributed not only to enhanced data tracking, but also better healthcare infrastructure, which has led to the better availability of specialty HAE products in the region.

Although the North America market is expected to grow at a healthy pace over the forecast years, it is expected to yield market share of ~4% to Europe and the Rest of the World, as public awareness about the disease rises in other parts of the world, shaping the further evolution of the hereditary angioedema treatment market.

hereditary angioedema treatment market infographic

To understand how our report can bring difference to your business strategy, Ask for a brochure

Subcutaneous Injection – Preferred Route of Administration

The intravenous route of medicine administration has been the method of choice for drugs used in the treatment of hereditary angioedema. This can be attributed to the fact that, conventional prophylactic drugs have traditionally been administered intravenously, and this method has occupied a significant share of the global hereditary angioedema treatment market in the last few years. However, with the development of drugs that can be administered orally and by subcutaneous injection, intravenous drugs are expected to lose popularity in the foreseeable future.

The phenomenal growth of subcutaneous injections as a mode of drug administration can be attributed to the demand for ease-of-usage for patients, which has had an instrumental impact on the growth of this segment. Where in 2018 subcutaneous injections accounted for close to half of the total market, by the end of the forecast period in 2027, this segment is anticipated to grow to occupy ~65% of the share.

Request a sample to get extensive insights into the Negatively Impact Market

New Therapies & Innovations Contributing to Hereditary Angioedema Treatment Market Growth

In recent years, there has been an impressive amount of research being done for the development of drugs for hereditary angioedema treatment. This has included not just drugs to control the symptoms of the illness, but also prophylactic treatment for HAE attacks. There are currently several drugs that are in various stages of approval for the long-term prophylactic treatment of HAE in children and adults. For instance, in May 2019, BioCryst Pharmaceuticals announced that its drug - BCX7353, for the prevention of (HAE) attacks, has achieved its primary endpoint for both dose levels.

Frequent Misdiagnosis of HAE to Negatively Impact Market

As with all rare genetic diseases, because the incidence of hereditary angioedema is lower in comparison to other illnesses, it is often overlooked and misdiagnosed as a different disease. The alarming rate of misdiagnosis of hereditary angioedema, globally, as common allergies, appendicitis, and Irritable Bowel Syndrome, has led to a delay in effective treatment, which has had a significant negative impact on the growth of the global hereditary angioedema treatment market.

Also restraining the growth of the market is the prohibitively high cost of the drugs used for hereditary angioedema treatment. Even as drug companies are working to introduce newer and better drugs for hereditary angioedema treatment, for both, acute attack and prophylactic treatments, cost management continues to remain an obstacle in the growth trajectory of the market.

hereditary angioedema treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Negatively Impact Market”

Hereditary Angioedema Treatment Market: Analysts’ Overview

The global hereditary angioedema treatment market is set to grow at a healthy pace during the forecast period, due to the gradually increasing awareness and diagnoses of rare genetic diseases, and product innovation for their treatment. According to analysts at Transparency Market Research, as newer and better classes of drugs are being made for a spectrum of symptoms and severity, players targeting their R&D toward the prophylactic treatment of hereditary angioedema attacks are likely to maximize their gains in the near future.

Subcutaneous injections are growing in popularity due to patient convenience and ease, being aided by the launch of innovative new products that employ this route of administration. Players in the market taking advantage of this preference in the development of medication for HAE are likely to gain a competitive edge in the hereditary angioedema treatment market.

The regional market in North America is expected to expand robustly, due to the large number of reported cases, coupled with a well-established healthcare infrastructure. The future is set to be lucrative for manufacturers focusing on ameliorating their product offerings to include personalized and speciality drugs for the treatment of hereditary angioedema.

Global Hereditary Angioedema Treatment Market and Report Description

  • Hereditary angioedema (HAE) is a rare and potentially life-threatening autosomal disease, characterized by swelling in the hands, feet, face, abdomen, upper airways, and other body parts. It occurs in 1 in 10,000 to 1 in 50,000 people.
  • HAE occurs due to improper functioning of a protein called C1 inhibitor, which affects the blood vessel.
  • Improper functioning of C1-INH protein results in increase of bradykinin concentration in the blood. This leads to accumulation of fluids outside the blood vessels, blocking the normal blood flow, and resulting in swelling of body organs.
  • Only a few drugs have been approved in major countries for the treatment of hereditary angioedema.
  • This disease can be treated using some of the approved drugs including C1 estearse inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and other conventional drugs such as attenuated drugs and antifibrinolytic agents.
  • Surge in awareness about hereditary angioedema and promising pipeline drugs & novel therapies are factors boosting the growth of the global hereditary angioedema treatment market.
  • The global hereditary angioedema treatment market was valued at ~US$ 2 Bn in 2018.
  • The global hereditary angioedema treatment market is projected to reach a value of ~US$ 5 Bn by 2027, expanding at a CAGR of ~9% from 2019 to 2027.

Hereditary Angioedema Treatment Market: Drivers

  • Surge in awareness about hereditary angioedema and rise in the prevalence of rare disorders across the globe are major factors boosting the growth of the global hereditary angioedema treatment market.
  • Approval of novel drugs in the past few years and promising pipeline drugs also fuel the growth of the global hereditary angioedema treatment market.
  • Moreover, rise in the intensity of severe attacks of edema due to high estrogen levels and increase in the usage of ACE inhibitors are other factors accelerating the growth of the hereditary angioedema treatment market.

Hereditary Angioedema Treatment Market: Notable Trends

  • Surge in the awareness about rare disorders and hereditary angioedema in the past few years is attributed to the growth of the global hereditary angioedema treatment market. Novel therapies, pipeline drugs, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE, are the major factors driving the global hereditary angioedema treatment market.
  • The oral route of administration is emerging as a trend in the hereditary angioedema treatment market, as a majority of the pipeline drugs are oral products. This route offers greater ease to patients and lesser side effects.
  • Companies strive to enter this rare diseases market with novel products in the pipeline. These players can enter the hereditary angioedema treatment market due to expiration of the market exclusivity of certain major products of established players in the next few years.

Hereditary Angioedema Treatment Market: Segment Analysis

  • Kallikrein inhibitors is anticipated to be a promising segment during the forecast period, owing to recently approved product – Takhzyro.
  • Recent launch and approval of the kallikrein inhibitor – Takhzyro - in the U.S., and expected launch of this drug in other markets is likely to drive the segment in the global hereditary angioedema treatment landscape.
  • Based on route of administration, the global hereditary angioedema treatment market can be divided into intravenous, subcutaneous injection, and oral. The subcutaneous injection segment is projected to dominate the global hereditary angioedema treatment market during the forecast period, owing to patient convenience and newly approved products.
  • In terms of distribution channel, the retail pharmacies segment dominated the global hereditary angioedema treatment market in 2018. The others segment is anticipated to be more attractive, owing to rise in the adoption of online pharmacies.

Global Hereditary Angioedema Treatment Market: Major Players

  • The report concludes with the company profiles section that includes key information about major players in the hereditary angioedema treatment market.
  • Key players analyzed in this report on the global hereditary angioedema treatment market are Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV. This section also includes companies such as Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals Ltd., and Attune Pharmaceuticals that have drugs in the pipeline, which are expected to launch in the new few years.
  • Robust R&D activities for pipeline products, new product approvals for specific indications, and strategic mergers & acquisitions are the key strategies adopted by major players in the global hereditary angioedema treatment market.
    • On January 7, 2019, Takeda Pharmaceutical Company Limited acquired Shire plc to form a strong value-based, biopharmaceutical global leading player.
    • In June 2017, CSL Limited launched HAEGARDA in the U.S. after strong research and development.
    • In August 2018, Shire plc received FDA approval for Takhzyro, a monoclonal antibody product, in the U.S., for the treatment of preventive hereditary angioedema.
    • In January 2017, the European Commission approved Pharming Group’s Ruconest for self-administration for acute HAE attacks in adolescents and adults.

Global Hereditary Angioedema Treatment market - Segmentation

TMR’s study on the global hereditary angioedema treatment market includes information divided into four sections: drug class, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global hereditary angioedema treatment market have been discussed in detail.

Drug Class

C1 Esterase Inhibitors

  • Plasma Products
    • Berinert
    • Cinryze
    • Haegarda
  • Recombinant Products
    • Ruconest

Selective Bradykinin B2 Receptor Antagonists

  • Firzyr

Kallikrein Inhibitors

  • Kalbitor
  • Takhzyro

Others

  • Conventional Drugs
  • Pipeline Drugs (BCX7353, KVD900)

Route of Administration

Intravenous

Subcutaneous Injection

Oral

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

Region

North America

Europe

Rest of the World

Frequently Asked Questions

Hereditary angioedema treatment market to Reach a value of ~US$ 5 Bn by 2027

Hereditary angioedema treatment market is projected to expand at a CAGR of ~9% from 2019 to 2027

Hereditary angioedema treatment market is driven by increase in awareness about hereditary angioedema and novel pipeline drugs

The subcutaneous injection segment dominated the global market, and the trend is likely to continue during the forecast period

Key players in the global hereditary angioedema treatment market are Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Orphan Drug Exclusivity Scenario

    5.3. Key Merger & Acquisitions

    5.4. Disease Overview

    5.5. Disease Prevalence-Global and Key Countries

6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. C1 Esterase Inhibitor

            6.3.1.1. Plasma Products

                6.3.1.1.1. Berinert

                6.3.1.1.2. Cinryze

                6.3.1.1.3. Haegarda

            6.3.1.2. Recombinant Products

                6.3.1.2.1. Ruconest

        6.3.2.  Selective Bradykinin B2 Receptor Antagonist

            6.3.2.1. Firazyr

        6.3.3.  Kallikrein Inhibitor

            6.3.3.1. Kalbitor

            6.3.3.2. Takhzyro

        6.3.4.  Others

            6.3.4.1. Conventional Drugs

            6.3.4.2. Pipeline Drugs

    6.4. Market Attractiveness By Drug Class 

7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2027

        7.3.1.  Intravenous

        7.3.2.  Subcutaneous Injection

        7.3.3.  Oral

    7.4. Market Attractiveness, by Route of Administration 

8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Others

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1.  North America 

        9.2.2.  Europe 

        9.2.3.  Rest of the World

    9.3. Market Attractiveness, by Country/Region

10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2027

        10.2.1. C1 Esterase Inhibitor

            10.2.1.1. Plasma Products

                10.2.1.1.1. Berinert

                10.2.1.1.2. Cinryze

                10.2.1.1.3. Haegarda

            10.2.1.2. Recombinant Products

                10.2.1.2.1. Ruconest

        10.2.2. Selective Bradykinin B2 Receptor Antagonist

            10.2.2.1. Firazyr

        10.2.3. Kallikrein Inhibitor

            10.2.3.1. Kalbitor

            10.2.3.2. Takhzyro

        10.2.4. Others

            10.2.4.1. Conventional Drugs

            10.2.4.2. Pipeline Drugs

    10.3. Market Value Forecast, by Route of Administration, 2017–2027

        10.3.1. Intravenous

        10.3.2. Subcutaneous Injection

        10.3.3. Oral

    10.4. Market Value Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Class 

        10.6.2. By Route of Administration 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

    11.1. .Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. C1 Esterase Inhibitor

            11.2.1.1. Plasma Products

                11.2.1.1.1. Berinert

                11.2.1.1.2. Cinryze

                11.2.1.1.3. Haegarda

            11.2.1.2. Recombinant Products

                11.2.1.2.1. Ruconest

        11.2.2. Selective Bradykinin B2 Receptor Antagonist

            11.2.2.1. Firazyr

        11.2.3. Kallikrein Inhibitor

            11.2.3.1. Kalbitor

            11.2.3.2. Takhzyro

        11.2.4. Others

            11.2.4.1. Conventional Drugs

            11.2.4.2. Pipeline Drugs

    11.3. Market Value Forecast, by Route of Administration, 2017–2027

        11.3.1. Intravenous

        11.3.2. Subcutaneous Injection

        11.3.3. Oral

    11.4. Market Value Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Class 

        11.6.2. By Route of Administration 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. C1 Esterase Inhibitor

            12.2.1.1. Plasma Products

                12.2.1.1.1. Berinert

                12.2.1.1.2. Cinryze

                12.2.1.1.3. Haegarda

            12.2.1.2. Recombinant Products

                12.2.1.2.1. Ruconest

        12.2.2. Selective Bradykinin B2 Receptor Antagonist

            12.2.2.1. Firazyr

        12.2.3. Kallikrein Inhibitor

            12.2.3.1. Kalbitor

            12.2.3.2. Takhzyro

        12.2.4. Others

            12.2.4.1. Conventional Drugs

            12.2.4.2. Pipeline Drugs

    12.3. Market Value Forecast, by Route of Administration, 2017–2027

        12.3.1. Intravenous

        12.3.2. Subcutaneous Injection

        12.3.3. Oral

    12.4. Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Route of Administration 

        12.5.3. By Distribution Channel 

13. Competitive Landscape

    13.1. Market Player - Competition Matrix (By Tier and Size of companies)

    13.2. Market Share Analysis, by Company, 2018

    13.3. Company Profiles

        13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Company Financials

            13.3.1.3. Growth Strategies

            13.3.1.4. SWOT Analysis

        13.3.2. CSL Limited

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Company Financials

            13.3.2.3. Growth Strategies

            13.3.2.4. SWOT Analysis

        13.3.3. Pharming Group N.V.

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Company Financials

            13.3.3.3. Growth Strategies

            13.3.3.4. SWOT Analysis

        13.3.4. Ionis Pharmaceuticals, Inc.

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Company Financials

            13.3.4.3. Growth Strategies

            13.3.4.4. SWOT Analysis

        13.3.5. BioCryst Pharmaceuticals, Inc.

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Company Financials

            13.3.5.3. Growth Strategies

            13.3.5.4. SWOT Analysis

        13.3.6. KalVista Pharmaceuticals Ltd.

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Company Financials

            13.3.6.3. Growth Strategies

            13.3.6.4. SWOT Analysis

        13.3.7. Attune Pharmaceuticals

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Company Financials

            13.3.7.3. Growth Strategies

            13.3.7.4. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis, by Phase III

Table 02: Pipeline Analysis, by Phase II and Phase I

Table 03: Pipeline Analysis, by Preclinical Trial 

Table 04: Orphan Drug Exclusivity

Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market

Table 06: Disease Overview by Type of HAE

Table 07: Reported and Estimated Cases of HAE, by Country

Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Hereditary Angioedema Treatment Market Value Share, by Drug Class, 2018

Figure 04: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018

Figure 05: Global Hereditary Angioedema Treatment Market Value Share, by Distribution Channel, 2018

Figure 06: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018

Figure 07: Global Hereditary Angioedema Treatment Market - Key Drivers and Restraints

Figure 08: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2017–2027

Figure 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2017–2027

Figure 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2017–2027

Figure 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 13: Global Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 14: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017–2027

Figure 16: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2017–2027

Figure 17: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 18: Global Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 19: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 20: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 21: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 22: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 23: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 24: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 25: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 26: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 27: North America Hereditary Angioedema Treatment Market Value Share, by Country, 2018 and 2027

Figure 28: North America Hereditary Angioedema Treatment Market Attractiveness, by Country, 2019–2027

Figure 29: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 30: North America Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 31: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 32: North America Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 33: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: North America Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 35: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 36: Europe Hereditary Angioedema Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 37: Europe Hereditary Angioedema Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 38: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 39: Europe Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 40: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 41: Europe Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 42: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 43: Europe Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 44: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 45: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 46: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 47: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 48: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 49: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 50: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 51: Global Hereditary Angioedema Treatment Market Share Analysis, by Company (2018)

Figure 52: Shire plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017

Figure 53: Shire plc, Breakdown of Net Sales (%), by Geography, 2017

Figure 54: Shire plc, Breakdown of Net Sales (%), by Therapeutic areas, 2017

Figure 55: Shire plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017

Figure 56: CSL Behring, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 57: CSL Behring, Breakdown of Net Sales (%), by Geography, 2018

Figure 58: CSL Behring, Breakdown of Net Sales (%), by Product Division/Therapy, 2018

Figure 59: CSL Limited, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 60: Pharming Group NV, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 61: Pharming Group NV, Breakdown of Net Sales (%), by Geography, 2018

Figure 62: Pharming Group NV, Region-wise Breakdown of Net Sales (%), by Ruconest, 2018

Figure 63: Pharming Group NV, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 64: Ionis Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 65: Ionis Pharmaceuticals, Inc., Breakdown of Net Sales (%), by Business Segment, 2018

Figure 66: Ionis Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 67: BioCryst Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 68: BioCryst Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 69: KalVista Pharmaceuticals Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 70: KalVista Pharmaceuticals Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Hereditary Angioedema Treatment Market